Adverum Biotechnologies Inc (ADVM)

$2.32 -0.07 (-2.93%)
Market Cap 48.47M
Revenue (ttm) 1.00M
Net Income (ttm) -130.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,093.00%
Debt to Equity Ratio 0.00
Volume 79,700
Avg Vol 218,358
Day's Range N/A - N/A
Shares Out 20.89M
Stochastic %K 9%
Beta 0.77
Analysts Strong Sell
Price Target $19.75

Company Profile

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a f...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 656 9323
Fax: 650 649 1995
Website: adverum.com
Address:
100 Cardinal Way, Redwood City, United States
twin_dad
twin_dad Aug. 3 at 12:14 AM
$ADVM buyout is coming
0 · Reply
somaopp
somaopp Jul. 29 at 7:20 PM
$ADVM wonder why they have so many at top level mgmt? lot of cash burn??
1 · Reply
alexx013
alexx013 Jul. 22 at 8:13 PM
$ADVM will run soon
0 · Reply
Cjtucktuck
Cjtucktuck Jul. 22 at 6:52 PM
$ADVM https://www.managedhealthcareexecutive.com/view/gene-therapy-for-rare-eye-disease-to-advance-to-human-trial Developed by $ADVM
1 · Reply
clockwatch2
clockwatch2 Jul. 22 at 12:25 AM
$ADVM its cooked
0 · Reply
twin_dad
twin_dad Jul. 20 at 5:10 PM
$ADVM
0 · Reply
alexx013
alexx013 Jul. 18 at 12:09 PM
$ADVM just kissed 3 premarket
0 · Reply
alexx013
alexx013 Jul. 17 at 12:44 PM
$ADVM will bust 3 soon, then 4, then 5...
0 · Reply
Dcainedwr
Dcainedwr Jul. 16 at 6:23 PM
$ADVM I love seeing the little bumps from time to time, but I can’t bring myself to buy any more of this… I need these bumps become *sustained gains.”
0 · Reply
liolio
liolio Jul. 16 at 5:08 PM
$ADVM “So we have cash into the second half of this year. So we are very confident in our ability to fund both phase three programs. Enrollment and then screening is going extremely well. It's actually above internal projections. So we feel very confident through the different levers that we have in front of us to finance a company from BD to equity to royalties based financing moving forward. So there's some levers that we have available that we are actively pursuing and more to come on that. Feel very confident just due to that very positive momentum.”
0 · Reply
Latest News on ADVM
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2025, 4:01 PM EDT - 2 months ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

May 14, 2025, 4:05 PM EDT - 2 months ago

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 30, 2025, 10:00 AM EDT - 3 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Shareholders to Inquire about Securities Investigation

Apr 29, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Shareholders to Connect

Apr 28, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation

Apr 25, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Adverum Biotechnologies, Inc. (ADVM) and Encourages Investors to Learn More About the Investigation

Apr 24, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Adverum Biotechnologies, Inc. (ADVM) and Encourages Investors to Learn More About the Investigation

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 23, 2025, 10:00 AM EDT - 3 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Connect

Apr 22, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation

Apr 20, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out

Apr 18, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out

Apr 17, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect

Apr 16, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Apr 15, 2025, 12:00 PM EDT - 3 months ago

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm

Apr 15, 2025, 9:09 AM EDT - 3 months ago

ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 4, 2025, 4:05 PM EDT - 4 months ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Mar 31, 2025, 4:01 PM EDT - 4 months ago

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Mar 3, 2025, 4:01 PM EST - 5 months ago

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 5 months ago

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 4:05 PM EST - 6 months ago

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 20, 2024, 4:05 PM EST - 9 months ago

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Nov 18, 2024, 1:37 PM EST - 9 months ago

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Nov 15, 2024, 4:05 PM EST - 9 months ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Nov 4, 2024, 4:39 PM EST - 9 months ago

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Oct 16, 2024, 8:00 AM EDT - 10 months ago

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Sep 4, 2024, 4:05 PM EDT - 11 months ago

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Jul 17, 2024, 3:35 PM EDT - 1 year ago

Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Jul 17, 2024, 2:45 AM EDT - 1 year ago

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

May 9, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

May 3, 2024, 8:00 AM EDT - 1 year ago

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Feb 8, 2024, 7:00 AM EST - 1 year ago

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

Feb 5, 2024, 7:45 AM EST - 1 year ago

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Feb 1, 2024, 5:30 PM EST - 1 year ago

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Jan 29, 2024, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

Dec 7, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

Nov 28, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Nov 9, 2023, 4:05 PM EST - 1 year ago

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.

Nov 6, 2023, 8:00 AM EST - 1 year ago

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Nov 4, 2023, 5:54 PM EDT - 1 year ago

Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

Sep 26, 2023, 4:05 PM EDT - 2 years ago

Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial

twin_dad
twin_dad Aug. 3 at 12:14 AM
$ADVM buyout is coming
0 · Reply
somaopp
somaopp Jul. 29 at 7:20 PM
$ADVM wonder why they have so many at top level mgmt? lot of cash burn??
1 · Reply
alexx013
alexx013 Jul. 22 at 8:13 PM
$ADVM will run soon
0 · Reply
Cjtucktuck
Cjtucktuck Jul. 22 at 6:52 PM
$ADVM https://www.managedhealthcareexecutive.com/view/gene-therapy-for-rare-eye-disease-to-advance-to-human-trial Developed by $ADVM
1 · Reply
clockwatch2
clockwatch2 Jul. 22 at 12:25 AM
$ADVM its cooked
0 · Reply
twin_dad
twin_dad Jul. 20 at 5:10 PM
$ADVM
0 · Reply
alexx013
alexx013 Jul. 18 at 12:09 PM
$ADVM just kissed 3 premarket
0 · Reply
alexx013
alexx013 Jul. 17 at 12:44 PM
$ADVM will bust 3 soon, then 4, then 5...
0 · Reply
Dcainedwr
Dcainedwr Jul. 16 at 6:23 PM
$ADVM I love seeing the little bumps from time to time, but I can’t bring myself to buy any more of this… I need these bumps become *sustained gains.”
0 · Reply
liolio
liolio Jul. 16 at 5:08 PM
$ADVM “So we have cash into the second half of this year. So we are very confident in our ability to fund both phase three programs. Enrollment and then screening is going extremely well. It's actually above internal projections. So we feel very confident through the different levers that we have in front of us to finance a company from BD to equity to royalties based financing moving forward. So there's some levers that we have available that we are actively pursuing and more to come on that. Feel very confident just due to that very positive momentum.”
0 · Reply
dthekang
dthekang Jul. 15 at 1:19 PM
$ADVM Get out people. Lol
0 · Reply
flinder1f7
flinder1f7 Jul. 14 at 4:22 PM
$ADVM
0 · Reply
MGeronimo
MGeronimo Jul. 10 at 10:30 PM
$ADVM IN AT 2.77 on good management and potential of product pipeline long term lottery play
1 · Reply
alexx013
alexx013 Jul. 10 at 3:17 PM
$ADVM started climbing
1 · Reply
dthekang
dthekang Jul. 2 at 2:54 PM
$ADVM nobody really gives shit abt this stock lol get out of the sinking ship if you are on it!
1 · Reply
clockwatch2
clockwatch2 Jul. 1 at 6:49 PM
$ADVM we got kicked off the russell 3000
2 · Reply
clockwatch2
clockwatch2 Jun. 30 at 1:53 PM
$ADVM
0 · Reply
Capitulation_0
Capitulation_0 Jun. 26 at 6:30 PM
$ADVM Mizhuo outperform 12 RBC 4 Chardan capital 33 HCW 30 No one fucking knows. oh Management bought in the 5,4,3s... So they don't fucking know.
0 · Reply
anachartanalyst
anachartanalyst Jun. 26 at 5:02 PM
$ADVM https://anachart.com/wp-content/uploads/ana_temp/1750957330_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Jun. 26 at 3:00 PM
Mizuho has updated their rating for Adverum Biotechnologies ( $ADVM ) to Outperform with a price target of 12.
1 · Reply
dthekang
dthekang Jun. 25 at 5:53 PM
$ADVM POS
0 · Reply
Kosmokrat
Kosmokrat Jun. 24 at 11:46 AM
$ADVM Currently Adverum runs the OPTIC, the LUNA, and the ARTEMIS trial to gather data an safety and efficacy of Ixo-Vec. But when do they plan to file for FDA approval? How much data will they need? Do you have any estimate on the timing of the FDA filing?
1 · Reply